No­var­tis pe­ti­tions Supreme Court in ef­fort to 'vig­or­ous­ly de­fend' Gilenya patent

No­var­tis has of­fi­cial­ly pe­ti­tioned the Supreme Court in an on­go­ing ef­fort to pro­tect Gilenya from gener­ic ri­vals for at least an­oth­er sev­er­al years.

The Swiss phar­ma gi­ant filed the 55-page doc­u­ment Wednes­day, af­ter an­nounc­ing its in­tent to pe­ti­tion the court in Sep­tem­ber. The case dates back to 2016, when HEC Pharm filed for gener­ic ap­proval of its own ver­sion of Gilenya, No­var­tis’s block­buster mul­ti­ple scle­ro­sis drug. The gener­ic won ap­proval in 2019, but No­var­tis fought back with law­suits as­sert­ing that var­i­ous patents don’t ex­pire un­til 2027.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.